564 related articles for article (PubMed ID: 21791425)
1. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
[TBL] [Abstract][Full Text] [Related]
2. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
3. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
[TBL] [Abstract][Full Text] [Related]
4. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
6. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
Rubnitz JE; Inaba H; Ribeiro RC; Pounds S; Rooney B; Bell T; Pui CH; Leung W
J Clin Oncol; 2010 Feb; 28(6):955-9. PubMed ID: 20085940
[TBL] [Abstract][Full Text] [Related]
7. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.
Ruggeri L; Mancusi A; Capanni M; Urbani E; Carotti A; Aloisi T; Stern M; Pende D; Perruccio K; Burchielli E; Topini F; Bianchi E; Aversa F; Martelli MF; Velardi A
Blood; 2007 Jul; 110(1):433-40. PubMed ID: 17371948
[TBL] [Abstract][Full Text] [Related]
8. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation.
Nguyen S; Béziat V; Norol F; Uzunov M; Trebeden-Negre H; Azar N; Boudifa A; Bories D; Debré P; Vernant JP; Vieillard V; Dhédin N
Transfusion; 2011 Aug; 51(8):1769-78. PubMed ID: 21332732
[TBL] [Abstract][Full Text] [Related]
9. Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation.
Ruggeri L; Capanni M; Mancusi A; Urbani E; Perruccio K; Burchielli E; Tosti A; Topini F; Aversa F; Martelli MF; Velardi A
Blood Cells Mol Dis; 2004; 33(3):216-21. PubMed ID: 15528134
[TBL] [Abstract][Full Text] [Related]
10. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
11. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
Shi J; Tricot G; Szmania S; Rosen N; Garg TK; Malaviarachchi PA; Moreno A; Dupont B; Hsu KC; Baxter-Lowe LA; Cottler-Fox M; Shaughnessy JD; Barlogie B; van Rhee F
Br J Haematol; 2008 Dec; 143(5):641-53. PubMed ID: 18950462
[TBL] [Abstract][Full Text] [Related]
12. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
Shimoni A; Labopin M; Lorentino F; Van Lint MT; Koc Y; Gülbas Z; Tischer J; Bruno B; Blaise D; Pioltelli P; Afanasyev B; Ciceri F; Mohty M; Nagler A
Leukemia; 2019 Jan; 33(1):230-239. PubMed ID: 29907809
[TBL] [Abstract][Full Text] [Related]
13. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.
Pende D; Marcenaro S; Falco M; Martini S; Bernardo ME; Montagna D; Romeo E; Cognet C; Martinetti M; Maccario R; Mingari MC; Vivier E; Moretta L; Locatelli F; Moretta A
Blood; 2009 Mar; 113(13):3119-29. PubMed ID: 18945967
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
Parisi S; Ruggeri L; Dan E; Rizzi S; Sinigaglia B; Ocadlikova D; Bontadini A; Giudice V; Urbani E; Ciardelli S; Sartor C; Cristiano G; Nanni J; Zannoni L; Chirumbolo G; Arpinati M; Lewis RE; Bonifazi F; Marconi G; Martinelli G; Papayannidis C; Paolini S; Velardi A; Cavo M; Lemoli RM; Curti A
Front Immunol; 2021; 12():804988. PubMed ID: 35173709
[TBL] [Abstract][Full Text] [Related]
16. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation.
Schulze A; Schirutschke H; Oelschlägel U; Schmitz M; Füssel M; Wassmuth R; Ehninger G; Bornhäuser M; Platzbecker U
Exp Hematol; 2008 Apr; 36(4):378-89. PubMed ID: 18261840
[TBL] [Abstract][Full Text] [Related]
17. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
18. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
[TBL] [Abstract][Full Text] [Related]
19. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
Koehl U; Sörensen J; Esser R; Zimmermann S; Grüttner HP; Tonn T; Seidl C; Seifried E; Klingebiel T; Schwabe D
Blood Cells Mol Dis; 2004; 33(3):261-6. PubMed ID: 15528141
[TBL] [Abstract][Full Text] [Related]
20. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
